Cardiovascular effects of detomidine, a new alpha 2-adrenoceptor agonist, in the conscious pony.

The research paper explores the cardiovascular effects of detomidine, a new alpha 2-adrenoceptor agonist, in comparison to xylazine in chronically instrumented and conscious ponies.

Methods

• The study was conducted on six ponies that were chronically instrumented with a micromanometer in the left ventricular chamber, a Doppler flow probe on a coronary artery, and sonomicrometer crystals in the left ventricular free wall.
• Measurements were taken of heart rate, ventricular systolic pressure, stroke work, dP/dtmax (rate of change of pressure with respect to time), minute work (a mechanical measure of heart’s oxygen demand), and coronary blood flow. These measurements were taken for 4 hours after the ponies were given intravenous injections of either detomidine at varying doses or xylazine at 1.1 mg/kg.

Results

• Both detomidine and xylazine caused a profound increase in blood pressure (hypertension) 15 seconds after injection. The increase in blood pressure was not found to increase further with detomidine doses greater than 20 micrograms/kg.
• The duration of the hypertension showed a dose-dependent response, with higher doses of detomidine leading to longer durations of hypertension.
• Both drugs led to a decrease in heart rate (bradycardia) and impairment of the electrical signals between the atria and ventricles of the heart (A-V blockade). These effects were of similar magnitude irrespective of the drug doses.
• Both detomidine and xylazine showed negative inotropic effects, meaning they decreased the force of contraction of the heart, at all doses.
• The minute work and coronary flow decreased to a similar level following all drug treatments, indicating a decrease in the heart’s oxygen demand and blood flow through the coronary arteries.

Conclusion

• Detomidine caused similar cardiovascular effects as the recommended dosage of xylazine, with the exception of a greater hypertensive response.
• The overall findings provide a comprehensive understanding of the cardiovascular impacts of detomidine and can help in making more informed decisions about its usage.